The pivotal Phase 2 trial (NCT04881760), published in The New England Journal of Medicine (Jastreboff et al., 2023), enrolled 338 adults with BMI 30 or higher
A healthy gut microbiome with diversity produces short-chain fatty acids, causing GLP-1 release
To qualify, youll need a BMI of 35 or higher alone or 27 or higher with additional criteria
Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A 26-week randomized controlled clinical trial
The most common side effects include: Gastrointestinal issues, like constipation, diarrhea, nausea and vomiting, due to the medications effect on digestion
A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control